Nature Outlook: Epilepsy [collection of free articles]
Clinical Trial Transparency — Antidote to Weaker Off-Label-Promotion Rules?
Keith Outterson. New England Journal of Medicine.
U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009.
Morgan-Linnell et al. Clinical Cancer Research.
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Stephen Strittmatter. Nature Medicine.
Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?
David Howard. New England Journal of Medicine.
FDA sets hierarchy for biosimilars evidence
Mark Ratner. Nature Biotechnology.
Clinical Trial Transparency — Antidote to Weaker Off-Label-Promotion Rules?
Keith Outterson. New England Journal of Medicine.
U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009.
Morgan-Linnell et al. Clinical Cancer Research.
Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks
Stephen Strittmatter. Nature Medicine.
Drug Companies' Patient-Assistance Programs — Helping Patients or Profits?
David Howard. New England Journal of Medicine.
FDA sets hierarchy for biosimilars evidence
Mark Ratner. Nature Biotechnology.
RSS Feed
